

Electronic Supplementary Material

Single Administration of Intracameral Bimatoprost Implant 10 µg in Patients With Open-Angle Glaucoma or Ocular Hypertension

Felipe A. Medeiros, MD, PhD,¹ Arsham Sheybani, MD,² Manjool M. Shah, MD,³ Marcos Rivas, PhD,⁴ Zhanying Bai, MS,⁵ Erica Werts, PharmD,⁴ Iqbal IK Ahmed, MD,⁶ E Randy Craven, MD⁴

¹Department of Ophthalmology, Duke University, Durham, North Carolina, USA; ²Department of Ophthalmology and Visual Sciences, Washington University in St. Louis School of Medicine, St. Louis, Missouri, USA; ³Kellogg Eye Center, Ann Arbor, Michigan, USA; ⁴Allergan, an AbbVie company, Irvine, California, USA; ⁵Allergan, an AbbVie company, Irvine, California, USA, at the time of this work; ⁶Department of Ophthalmology, University of Toronto, Mississauga, Ontario, Canada

Corresponding author: Felipe A. Medeiros, MD, PhD; Duke Eye Center, 2351 Erwin Rd, Durham, NC, USA 27705; E-mail: felipe.medeiros@duke.edu

Table S1. Baseline Demographics of the 10- μ g Bimatoprost Implant Treatment Group in the Phase 1/2 Study

Characteristic	10- μ g Bimatoprost Implant (N=21)
Age, mean (SD), years	65.4 (6.6)
Range	52–77
Male, n (%)	12 (57.1)
Race/ethnicity, n (%)	
White	15 (71.4)
Black or African American	4 (19.0)
Hispanic	1 (4.8)
Asian	1 (4.8)
Diagnosis, n (%)	
POAG (both eyes)	21 (100)
Lens status, n (%)	
Phakic (both eyes)	14 (66.7)
Pseudophakic (both eyes)	7 (33.3)
IOP, mean (SD), mmHg	
Hour 0 (8 AM) (study eye)	24.5 (2.1)
Hour 2 (10 AM) (study eye)	23.6 (1.9)
Hour 0 (8 AM) (fellow eye)	24.1 (2.1)
Hour 2 (10 AM) (fellow eye)	23.1 (2.4)
CECD, mean (SD), μ m	
Study eye	2691.3 (175.7)
Fellow eye	2650.4 (201.9)

CECD = central corneal endothelial cell density; IOP = intraocular pressure;
POAG = primary open-angle glaucoma; SD = standard deviation.